Wishing all our readers a safe and happy Memorial day weekend. Following find the latest news from Clearly Canadian (CCBEF) and Dutch Gold Resources (DGRI).

We have also added two companies to our Focus list. Bioenvision (BIVN) is a company that has been on fire as of late attracting investments from the Soros Fund among others. Radyne (RADN) is just the opposite, it continues to be beaten down to a point where it has become very attractive. To learn more these companies and others, visit our site here.

Press Release: Dutch Gold Resources Further Enhances Mill to Process Free Gold

Announced that it has installed a Knelson Concentrator at its Merlin Mill near Grant's Pass, Oregon, following the recent discovery of unusually high amounts of free gold, not commonly seen in structures such as the zones being developed. The Knelson Concentrator is said to offer the most efficient and highest precious metal recovery performance in the industry. Installation of the Knelson concentrator follows the company's recent announcement it has increased capacity at the mill from 120 tons of ore per day (TPD) to 330 TPD.

Separately, Mr. Hollis reported, "Our efforts to bring the Company into full reporting status are progressing, and we anticipate completion of our audit during the second quarter."

Profile

Bioenvision (BIVN) primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra, Modrenal (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing Suvus which is currently in clinical development for refractory chronic hepatitis C infection.

The company also offers various anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices. In addition, it provides an animal health product, Vetoryl, for the treatment of Cushing's disease in dogs; and Velostan, a cytostatic drug under investigation as an anticancer agent and as an antimicrobial. The company sells its products to wholesale distributors and directly to hospitals, clinics, and retail pharmacies in the United States and the United Kingdom. It has co-development partnership with Genzyme Corporation. 

BIVN Investor Highlights

• Bioenvision has teamed up with Genzyme Corp. to develop clofarabine, a treatment for leukemia in children, the magazine said. Bioenvision aims to expand its use for elderly patients with acute myeloid leukemia in Europe, where it has marketing rights.
• Steven Rouhandeh, chief executive of SCO, is quoted by BusinessWeek as saying that when Europe approves clofarabine for adults, "Bioenvision will rocket," adding that by then, Genzyme might opt to buy Bioenvision. A decision is expected in 2007.
• Soros Fund Management and Perseus-Soros BioPharma Fund own a combined 12 percent stake in BIVN according to BusinessWeek. 

Read more about BIVN here.

Radyne (RADN)

Website: www.radn.com

Communication Solutions That Keep You Up To Speed.

RADN Investor Highlights

• Reported quarterly bookings of $35.4 million, the second strongest bookings quarter in the company's history. Bookings for the first quarter of 2006 were $32.7 million. Backlog at quarter end stood at $31.1 million.
• Received follow-on orders for over $4.1 million of DM-240 satellite modulators, DD-240 broadcast receivers and related accessories from a major direct-to-home (DTH) television broadcast distributor. The orders will ship during the second quarter.
• Announced that its Xicom Technology subsidiary received an order for $3.6 million for power amplifiers as an additional procurement for the Ground Multi-Band Terminal (GMT) program. The amplifiers are scheduled to ship during 2007.
• Announced that its Xicom Technology division received a follow-on procurement order for $1.4 million for Ka-band power amplifiers to be used in terminals for the U.S. Air Force's Wideband Global System
• Received more than $6.7 million in follow-on orders from DirecTV Group Inc. for power amplifiers and satellite modulators. The orders, to be used in the DirecTV's high-definition TV expansion, are shipping during the first three quarters of 2007.
• Received an order for $1 million of its new DMD-50 high speed satellite modem from an Asian defense agency. The DMD-50 is one of Radyne's new generation of modems that addresses the need for cost-effective, high-speed communications supporting up to 50 Mbps.

Profile

Radyne Corporation (RADN) designs, manufactures, sells, integrates and installs products, systems and software used for the transmission and reception of data and video over satellite, troposcatter, microwave and cable communication networks. 

The Company, through its Tiernan subsidiary, is a supplier of HDTV and SDTV encoding and transmission equipment. The Xicom Technology subsidiary is a producer of high power amplifiers for communications applications. Radyne is headquartered in Phoenix, Arizona, has manufacturing facilities in Phoenix, Arizona, San Diego, California, and Santa Clara, California and sales offices in Singapore, Beijing, Jakarta and the United Kingdom. The Company also has sales and/or service centers in Sao Paulo, Bangalore, Shanghai and Moscow.

Radyne Corporation is structured into three business units to maintain sharp focus on the key technologies and products its customers need and demand.

Read more about RADN here.

SmallCapReview feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of  CCBEF, DGRI, BIVN and RADN please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.  

Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SCR web site. SCR has been compensated thirty thousand dollars by Clearly Canadian and was previously compensated seventeen thousand dollars by Level 3 Research for its efforts in presenting the CCBEF profile on its website and distributing it to its database of subscribers. SCR has been compensated thirteen thousand dollars by a third party (Xsellmarketing) for its efforts in presenting the DGRI profile on its website and distributing it to its database of subscribers. SCR has not been compensated for its efforts in presenting the RADN or BIVN profiles on its website and distributing it to its database of subscribers. SCR may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report.

The Reader should verify all claims and do their own due diligence before investing in any securities mentioned. Investing in small-cap securities is speculative and carries a high degree of risk.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.